GLP-1 Goal Weight Calculator
A healthy BMI range for your height — and how far it is from where the trials landed.
Healthy weight range (BMI 18.5–24.9)
111.2–149.6lb
Classic ideal-weight formulas
Devine
125.7lb
Robinson
126.8lb
Miller
132.1lb
Hamwi
124.6lb
“Ideal weight” is a rough target, not a verdict — these formulas ignore muscle, frame, and body composition. The BMI range up top is the more useful goalpost, and on a GLP-1 your body-fat and waist trends matter more than any single number.
How much do you have to lose to reach a healthy BMI?
There is one line of arithmetic behind this, and it is independent of height: the loss needed to reach the top of the healthy band is 1 − (24.9 ÷ your starting BMI). Written out:
| Starting BMI | Loss needed to reach BMI 24.9 |
|---|---|
| 27 | 8% |
| 30 | 17% |
| 32 | 22% |
| 35 | 29% |
| 38 | 34% |
| 40 | 38% |
| 45 | 45% |
| 50 | 50% |
Now read it against what the trials actually produced. The mean loss in the best arm of the largest tirzepatide obesity trial was 20.9%, and 14.9% in the semaglutide 2.4 mg trial. Against the table, that clears the healthy band from a starting BMI of about 31 on tirzepatide and about 29 on semaglutide — and those trials enrolled people averaging BMI 38.
Which means, plainly: for most people the healthy band is not the goal of this course of treatment. A goal weight set at a formula's number can be a target the medication was never going to hit — and that is a reason to set the target differently, not a reason to treat the result as a failure. The clinically meaningful thresholds sit far below the healthy band: 5–10% is where the health markers move. If the number stops moving well before you expected it to, that is its own problem with its own answers — what to do when Ozempic weight loss plateaus.
What the trials actually reached
| Trial | Drug | Mean weight change | What it means for a goal weight |
|---|---|---|---|
| SURMOUNT-1 (72 weeks) | Tirzepatide 15 mg | −20.9% | Mean baseline BMI 38.0, so an average endpoint near BMI 30 (derived: 38.0 × 0.791) |
| STEP 1 (68 weeks) | Semaglutide 2.4 mg | −14.9% (−15.3 kg); placebo −2.4% (−2.6 kg) | Roughly a quarter of the distance from BMI 38 to the healthy band |
| SURMOUNT-5 (72 weeks) | Tirzepatide vs semaglutide | −20.2% vs −13.7% | Head-to-head, same order of magnitude |
One label to be scrupulous about: the "endpoint near BMI 30" figure is derived arithmetic on two numbers from the same publication — the mean baseline BMI and the mean percentage change — not a reported SURMOUNT-1 outcome. And all of these are means. SURMOUNT-1 reported that 94.5% of participants started at BMI 30 or above, and individual results spread widely either side of the average. If you want the shape of the loss over time rather than its endpoint, that is the 12-month GLP-1 weight-loss projection curve.
Ideal weight formulas: Devine, Robinson, Miller and Hamwi
The healthy-weight band at the top of this tool is arithmetic you can check: weight in kg equals BMI multiplied by your height in metres squared, worked at both ends of the 18.5–24.9 band. Everything else on the page is a formula — Devine, Robinson, Miller and Hamwi — and each one is just a base weight plus a fixed number of kilos for every inch above five feet. They differ only in the base and the increment, which is the entire reason they disagree with each other.
| Female, 5'5" (165 cm) | Male, 5'10" (178 cm) | |
|---|---|---|
| Healthy range (BMI 18.5–24.9) | 111–150 lb | 129–174 lb |
| Devine | 126 lb | 161 lb |
| Robinson | 127 lb | 157 lb |
| Miller | 132 lb | 155 lb |
| Hamwi | 125 lb | 165 lb |
Two things jump out. The four formulas span about 7 lb at one height and 10 lb at the other, so no single one of them is the ideal weight. And they all sit low inside the healthy band: converted back to BMI, the female figures land around 21 and the male figures around 22 to 24, while the band itself runs to 24.9. Roughly the top quarter of a perfectly healthy weight range never appears in any formula output.
The trap: a single number that ignores what you are made of
None of these formulas take an input for body composition, because none of them have one. A powerlifter and a sedentary person of the same height and sex get the identical answer. That is not a rounding problem, it is the design: the formulas were built from small mid-twentieth-century datasets to produce a quick height-based estimate, and they carry no information about muscle, frame or fat distribution.
Which makes the output a reference point, not a clinical target. The tool cannot see your waist, your training history, or what your bloods look like, and it does not know why you are asking. A goal weight is something to set with your prescriber, who can weigh those things against the number.
What matters more once you are losing
When weight comes off, some of it is lean mass, and the honest figures are larger than most people expect. DXA sub-studies found about 26% of the weight lost on tirzepatide was lean tissue, and about 40% on semaglutide. The number that changes how you read those: the diet-and-exercise placebo group lost the same 25% share as lean. Lean loss is a property of losing weight, not something these medications do to you. The full comparison is in Zepbound vs Wegovy muscle loss.
Two caveats matter. DXA "lean mass" is not muscle — it includes organs and body water, both of which shrink as you get smaller. And when muscle was measured directly by MRI in a tirzepatide trial, the volume lost matched what would be predicted for that amount of weight loss, while fat infiltration within the muscle fell more than predicted. That is a better outcome than the DXA percentage alone implies.
The practical consequence is that the scale reaching a formula's number tells you nothing about the composition of the trip. Waist measurement, how your clothes fit, grip and general strength, and whether you are clearing a daily protein target for GLP-1 weight loss while training are all more informative than closing the last few pounds to a target. Put another way, the composition of the loss is a better goal than the endpoint number — which is also why a shot tracker that only logs weight misses body composition.
Where this tool does not apply
Under five feet, the formulas have no increment left to subtract — the tool floors the per-inch term at zero, so every height below 60 inches returns the same base weight. Treat those outputs as meaningless and use the BMI range instead. The BMI band itself is for adults, not children, who are assessed against age-and-sex growth charts, and it is not a guide in pregnancy.
BMI thresholds are also not applied identically everywhere: some national guidelines use lower cut-offs for particular ethnic groups, so confirm which band your clinician works to. And a high BMI carried as muscle is a well-known false positive. If the number looks wrong for your body, it probably is — that is the limitation of a formula with one input.
One more: this is not a prescribing threshold. Eligibility for these medications is set by BMI cut-offs plus comorbidities that vary by country and by payer, and a healthy-band goal has nothing to do with whether treatment is indicated. Nor does any of it replace the daily nutrition floors that make the loss survivable — the daily fibre target on a GLP-1 is the usual first gap once appetite drops.
Frequently asked
- What should my goal weight be on Mounjaro or Zepbound?
- The healthy BMI band for your height (18.5 to 24.9) is the reference point, but the reachable target is your starting weight minus a realistic percentage. The trial means are 20.9% for tirzepatide 15 mg over 72 weeks and 14.9% for semaglutide 2.4 mg over 68 weeks. Set the actual number with your prescriber, who knows your starting point and your health markers.
- Will a GLP-1 get me to a normal BMI?
- For many people, no — and that is the expected result rather than a failure. The average SURMOUNT-1 participant started at BMI 38.0 and lost 20.9% on 15 mg tirzepatide, which works out at an endpoint near BMI 30. That is derived arithmetic on the trial means, and means hide a wide spread. The health benefits show up at 5 to 10% loss, long before the healthy band.
- How much weight do I need to lose to have a healthy BMI?
- One line of arithmetic: 1 minus (24.9 divided by your current BMI). From BMI 30 that is about 17%; from BMI 38 it is about 34%; from BMI 45 it is about 45%. It does not depend on your height. Compare the answer against what the trials averaged before you set it as a target.
- What is a healthy weight for my height?
- The range corresponding to a BMI of 18.5 to 24.9 at your height, which for a 5 foot 5 adult is roughly 111 to 150 lb and for 5 foot 10 is roughly 129 to 174 lb. You can check it yourself: weight in kg equals BMI multiplied by height in metres squared. It is a range rather than a point, and a wide one.
- Which ideal-weight formula is the most accurate?
- None of them, in any strong sense. Devine, Robinson, Miller and Hamwi are each a base weight plus a fixed amount per inch above five feet, differing only in those two constants, which is why they disagree by 7 to 10 lb at the same height. They come from small mid-twentieth-century datasets and were never validated as clinical targets.
- Why do the formulas give a number below the middle of the healthy range?
- Converted back to BMI, the formula outputs cluster around 21 for women and 22 to 24 for men, while the healthy band runs to 24.9. So the top portion of a healthy weight range never appears in any formula result. Being above a formula number does not put you outside a healthy weight.
- Should I use the formula figure as my goal weight?
- Treat it as a reference point rather than a target. The formulas take height and sex only, so they cannot account for muscle, frame or fat distribution, and they were not designed to set goals. Setting an actual target is a conversation with your prescriber, who can factor in your starting point and your health markers.
- Does this work if I lift weights or carry a lot of muscle?
- Poorly. A lifter and a sedentary person of the same height and sex get the same answer, because neither BMI nor any of these formulas has an input for body composition. Waist circumference and your body-fat trend are more useful measures in that case.
- Will I lose muscle getting to a healthy weight on a GLP-1?
- Some lean mass comes off with any weight loss. DXA sub-studies put lean tissue at about 26% of the weight lost on tirzepatide and about 40% on semaglutide, but the diet-and-exercise placebo group lost the same 25% share, so this is a feature of losing weight rather than of the drug. DXA lean mass also includes organs and water, and when muscle was measured directly by MRI the volume lost was in line with prediction for that amount of weight loss.
Related calculators
- GLP-1 Fiber CalculatorYour daily fiber goal — and easy ways to hit it.
- GLP-1 Protein Calculator for Zepbound & WegovyYour daily protein floor — and which body weight the g/kg actually applies to.
- How Much Water to Drink on a GLP-1A daily target in litres, cups and oz — and the weeks it has to go up.
- Dose Titration PlannerYour label-based escalation ladder, mapped week by week.
Read next
- Why scale weight hides muscle lossDoes Mounjaro cost more muscle than Ozempic? See the SURMOUNT & STEP lean-mass data, the protein floor that protects it, and how to track it. Not medical advice.
- When the scale stops movingStalled on Ozempic? A prioritised, trackable plateau plan: protein floor, injection-site rotation, dose check with your prescriber, and the non-scale trend.
- Keeping the loss after you stopHow much weight comes back after stopping a GLP-1, why it happens, and why regaining the number doesn't mean regaining the same body composition.
Sources
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022) — Mean baseline body weight 104.8 kg, mean BMI 38.0, 94.5% with BMI ≥30. Mean weight change at week 72: −15.0% on 5 mg, −19.5% on 10 mg, −20.9% on 15 mg and −3.1% on placebo
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021) — Mean change in body weight at week 68: −14.9% (−15.3 kg) versus −2.4% (−2.6 kg) on placebo
- Aronne LJ, et al. Tirzepatide versus Semaglutide for Obesity (SURMOUNT-5, NEJM 2025) — Head-to-head: −20.2% with tirzepatide versus −13.7% with semaglutide at week 72
- WHO — Obesity and overweight fact sheet — Overweight defined as BMI ≥25 and obesity as BMI ≥30 in adults — the basis for the statement that a BMI-30 endpoint is still within the obesity range
- SURMOUNT-1 DXA sub-study — body composition with tirzepatide (Diabetes Obes Metab 2025) — Weight lost was 74% fat and 26% lean with tirzepatide against 75% and 25% with diet and exercise alone, a statistically indistinguishable split. Defines DXA lean mass as including organs and water
- STEP 1 DXA sub-study — body composition with semaglutide (J Endocr Soc 2021) — Lean tissue accounted for about 40% of combined fat and lean mass lost
- SURPASS-3 MRI — muscle volume measured directly (Lancet Diabetes Endocrinol 2025) — Muscle volume loss matched the UK Biobank prediction for that degree of weight loss, while muscle fat infiltration fell more than predicted
- Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant? (JAMA 2024) — Viewpoint on how to interpret lean mass changes during weight loss
Medical disclaimer. Tiro is a tracking companion, not a medical device, and nothing on this site is medical advice. Always follow the titration schedule and dosing instructions from your prescriber. Never change your dose without talking to them first.
